Keeping abreast of the most current treatments for idiopathic OAB can lead to improved outcomes and quality of life.
David O. Sussman, DO, has been ready to educate urology colleagues on the appropriate use of Botox.
A new trial has found that mirabegronreduced the frequency of incontinence episodes and number of daily urinations in adults with overactive bladder.
Elderly patients with OAB may benefit from combined high-dosage antimuscarinics.
Repeat injections of onabotulinumtoxinA (BTXA) appear to benefit patients with non-neurogenic overactive bladder.
Improvements in efficacy and quality of life last at least six months, study finds.
Depression risk greater for men with nocturia than for women with nocturia.
Two studies show significant reduction in number of nocturnal voids for women.
In most responders, overactive bladder symptom improvement sustained to three years.
Products advertised through fax; not FDA approved.
Oxytrol is intended for use by those 18 and older.
Increasing the daily dose from 5 to 10 mg resulted in reductions in mean total urgency score and mean micturition frequency.
The FDA has approved onabotulinumtoxinA (Botox) as a treatment for overactive bladder (OAB) in adults who are inadequately managed with anticholinergic medications.
Patients with type 2 diabetes are twice as likely as nondiabetics to suffer from the condition.
Mirabegron is the first oral OAB drug with a distinct mechanism of action to be approved in three decades.
Flexible-dose fesoterodine is superior to placebo in decreasing the number of nocturnal urgency episodes and nocturnal micturitions in patients with overactive bladder (OAB), researchers reported at the American Urological Association 2012 annual meeting.
Patients with overactive bladder (OAB) say they are most bothered by symptoms of urinary urgency either as a primary complaint or as a driving symptom for frequency, according to a pilot study presented at the American Urological Association 2012 annual meeting.
Diabetes has no influence on intravesical botulinum toxin type A (BoNTA) injection in overactive bladder (OAB) patients, researchers reported at the American Urological Association 2012 annual meeting.